Mirum Pharmaceuticals announced on October 21, 2026, that the U.S. Food and Drug Administration granted orphan drug designation to brelovitug for active hepatitis delta virus infections. The designation provides development incentives for the investigational treatment, but it is not permission to market the drug.
Key Takeaways
- The FDA orphan designation covers brelovitug for active hepatitis delta virus infections.
- Brelovitug remains investigational; the designation does not establish safety or effectiveness.
- Mirum’s pipeline lists AZURE-4 topline data as expected in the fourth quarter of 2026.
Table of Contents
- Mirum Pharmaceuticals adds a rare-disease development incentive
- Brelovitug targets a protein shared by hepatitis D and B
- Conclusion
Mirum Pharmaceuticals adds a rare-disease development incentive
Orphan drug designation is intended to encourage development of treatments for rare diseases. It can provide access to incentives such as tax credits and potential grant funding, with market exclusivity available if the treatment subsequently receives approval and meets the applicable requirements.
For Mirum, the announcement concerns the development pathway for a pipeline medicine rather than a new commercial product. It does not itself establish that brelovitug is safe or effective, and it should not be read as an approval decision.
Mirum is a commercial-stage biopharmaceutical company with existing medicines for rare liver and metabolic diseases. Brelovitug would address a different treatment need from those served by its established portfolio.
| Item | Details |
|---|---|
| Livmarli | Maralixibat; approved for cholestatic pruritus in specified rare liver diseases. |
| Cholbam | Cholic acid; used to treat certain bile acid synthesis disorders. |
| Ctexli | Chenodiol; approved for adults with cerebrotendinous xanthomatosis. |
Brelovitug targets a protein shared by hepatitis D and B
Mirum’s description of brelovitug’s mechanism explains that the investigational, fully human monoclonal antibody targets hepatitis B surface antigen, a protein found on both hepatitis D and hepatitis B viruses. The approach is designed to help neutralize virus particles and support their removal from the bloodstream.
The company describes brelovitug as being evaluated in AZURE, a global Phase 3 clinical development program for chronic hepatitis delta virus. Its studies assess a combined virologic and biochemical response, keeping clinical evidence central to the program’s progress.
Mirum’s pipeline lists AZURE-4 topline results as expected in the fourth quarter of 2026. That is a planned clinical milestone, not a confirmed regulatory submission or approval date.
Conclusion
The orphan designation adds development support without changing brelovitug’s investigational status. The next identified clinical milestone is the planned AZURE-4 topline readout in the fourth quarter of 2026.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
